OnKO T&T 2 0: Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) for Adolescents and Young Adults Diagnosed With Cancer

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05350631
Collaborator
(none)
200
7
2
25
28.6
1.1

Study Details

Study Description

Brief Summary

Approximately 2,200 cancers per year in France are diagnosed within the adolescents and young adults population (15-25 years old, AYA). The cancer plans and the INCA recommend support during and after cancer treatment, taking into account both medical and psycho-social specificities related to age (support care, school learning/training and professional integration, fertility preservation, therapeutic education, addictology, sexology...). In this context, AJA teams have been developed in which the Nurse Coordinators (IDEC) play a fundamental role. These Nurse Coordinators are available to young patients, their families and the professionals who accompany follow them in their therapeutic journey. Their main missions are to assess the specific needs of these young people and their loved ones, to inform, orient and participate in the coordination of their care by providing psychosocial and paramedical solutions to these young patients. The circular of 30/05/2016 on the coordinated regional organization of care for AJAs supports the development of connected health tools for AJAs. This population is adept to new technologies, social networks allowing them to continue to be informed and remain integrated to the outside world while helping them prepare for life after cancer.

In this context, our team initiated the development of a digital application compatible for any cellphone OnKO-Tips&Tricks meeting these criteria of necessity with the company CAPCOD. We would want to move on to a validation stage by carrying out a national multicenter efficacy study in AJA mobile units by comparing two groups of patients: users/non-users of this digital tool on a main criterion of quality of life after using it for 6 months. As it should promote autonomy and integration into the care pathway as well as active participation in therapeutic education programs (TPE), these different items will be evaluated as secondary endpoints of our study

Condition or Disease Intervention/Treatment Phase
  • Other: OnKO-Tips&Tricks digital phone application
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) Allowing Daily Follow-ups, Implementation of an ETP Program and a Direct Link With the Nurse Coordinator of Units Specifically Dealing With Adolescents and Young Adults Diagnosed With Cancer
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

only follow-ups consultations, phone contact and TVE workshop with the AJA mobile team centralized by the IDEC

Experimental: Experimental

using a digital tool in addition to follow-ups by consultations, phone contact and PTE workshop with the AJA mobile team centralized by the IDEC

Other: OnKO-Tips&Tricks digital phone application
Using daily OnKO-Tips&Tricks digital phone application

Outcome Measures

Primary Outcome Measures

  1. Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the psychosocial dimension of patients' quality of life [6 months of inclusion]

    Assessed using a psychosocial health score obtained by the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire. The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.

Secondary Outcome Measures

  1. Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the psycho-social dimension of patients' quality of life [3 months and 12 months of inclusion]

    Assessed using a psychosocial health score obtained from the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire. The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.

  2. Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on patients' overall and physical quality of life [3 months, 6 months and 12 months of inclusion]

    Assessed using total Quality of Life and physical health subscore scores obtained from the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire. The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.

  3. Evaluate the impact on each patient's participation in a therapeutic education program (TPE) [through study completion, an average of 1 year and 6 months]

    Rate of patients in the experimental and control groups who will participate in the proposed FTE program

  4. Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application throughout the patient's care pathway [3 months, 6 months and 12 months of inclusion]

    assessed by the number of consultations, medical and paramedical, the number of outpatient management, the number of unscheduled hospitalizations, the number of listed side effects, and the number of phone contacts (text, calls) and emails initiated by the patient towards the IDEC.

  5. Assess patient satisfaction with the use of the OnKO-Tips&Tricks digital phone application using the MAUQ questionnaire [6 and 12 months]

    Evaluated using the mHealth app usability questionnaire (MAUQ questionnaire).

  6. Evaluate the adherence to the application in the experimental group [Per week and per month through study completion, an average of 1 year and 6 months]

    Evaluated by collecting the number of uses of each feature

  7. Evaluate the efficacy of the OnKO-Tips&Tricks digital phone application on the quality of life of patients according to cancer pathology [6 months of inclusion]

    Comparative analysis of quality of life collection using the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales questionnaire taking into account the type of cancers: solid vs. blood cancer The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 25 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient age ≥ 15 years and ≤ 25 years

  • Diagnosed with solid or blood cancers less than 1 month old or patient with relapsed cancer more than 5 years after completion of initial treatment

  • Follow-up at one of the participating study centers

  • Informed and signed consent from the patient and, if the subject is a minor, from the holders of parental authority

  • Inclusion in the study at the latest at the time of initiation of chemotherapy or radiotherapy

  • Patient agrees to 12-month post-inclusion follow-up

  • Patient agreeing to complete all study questionnaires

  • Patient with a cellphone capable of downloading the app (developed for all types of cellphones)

  • Affiliated to a social health insurance plan

Exclusion Criteria:
  • Patient deprived of liberty by a judicial or administrative decision

  • Patient with protected person status

  • Patient who does not understand, speak or write French

  • Patient unable to understand the follow-up protocol according to the investigating physician or the IDEC of the AJA unit

  • Patient with a scheduled hospitalization of at least 5 weeks during study participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut d'Hématologie et d'Oncologie Pédiatrique Lyon France 69 008
2 Hôpital enfant-adolescent Nantes France 44093
3 CHU de Nice Hôpital Archet 2 Nice France 06202
4 CHU Reims - Hôpital Maison Blanche Reims France 51092
5 CHU Rennes Hôpital Sud Rennes France 35200
6 Institut de Cancérologie de l'Ouest Saint-Herblain France 44805
7 Hôpitaux Universitaires de Strasbourg Strasbourg France 67091

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT05350631
Other Study ID Numbers:
  • 8360
First Posted:
Apr 28, 2022
Last Update Posted:
May 9, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Strasbourg, France

Study Results

No Results Posted as of May 9, 2022